Biosimilar infliximab administration for the management of acute graft-versus-host disease
| Autor: | Amanda N. Seddon, Paul Fitzpatrick, Rebecca Myers, Eris Tollkuci, Celalettin Ustun, Sunita Nathan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_treatment Graft vs Host Disease Disease 03 medical and health sciences 0302 clinical medicine immune system diseases Acute graft versus host disease Medicine Humans Pharmacology (medical) Biosimilar Pharmaceuticals business.industry Tumor Necrosis Factor-alpha Hematopoietic Stem Cell Transplantation Immunosuppression Biosimilar Middle Aged Infliximab surgical procedures operative Oncology 030220 oncology & carcinogenesis Immunology Acute Disease Female Allogeneic hematopoietic stem cell transplant business Complication 030215 immunology medicine.drug |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(8) |
| ISSN: | 1477-092X |
| Popis: | Introduction Acute graft-versus-host disease (aGVHD) is a significant immune-mediated complication of allogeneic hematopoietic stem cell transplant (HSCT). Despite prophylactic immunosuppression, the incidence of grades II–IV aGVHD post-HSCT varies from 20 to 80%. Tumor necrosis factor (TNF) is an important cytokine involved in the pathogenesis of GVHD, and medications such as infliximab (Remicade®) have been utilized as second-line treatment options in patients with steroid-refractory GHVD. Infliximab-dyyb (Inflectra®) and infliximab-qbtx (Ixifi®) are biosimilars approved by the FDA for a variety of autoimmune disorders. This is the first case report documenting the utility of infliximab-dyyb and -qbtx for the management of steroid-refractory aGVHD. Case report We report the post-transplant course of three patients treated with infliximab biosimilars as a part of therapy for management of steroid-refractory aGVHD. Management and outcome Steroid-refractory aGVHD is associated with poor prognosis and its management, as highlighted in our three patient cases, and can be very diverse often requiring different therapeutic modalities which overlap in administration. Discussion In these patients with steroid-refractory aGVHD, we were able to show that infliximab biosimilars could be used in lieu of the reference infliximab product. Although we had important limitations, this case report supports the use of anti-TNF agents in highly mortal steroid-refractory acute GI GVHD and that replacement of infliximab with its biosimilars is feasible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|